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Abstract Bladder pain syndrome/interstitial cystitis (BPS/
IC) is a chronic disease characterised by persistent irritating
micturition symptoms and pain. The objective was to compare
the clinical efficacy of currently available products for
intravesical therapy of BPS/IC and to assess their
pharmacoeconomic impact. A Pubmed/Medline database
search was performed for articles on intravesical therapy for
BPS/IC. A total of 345 publications were identified, from
which 326 were excluded. Statistical evaluation was per-
formedwith effect size (ES) assessment of symptom reduction
and response rates. The final set of 19 articles on intravesical
BPS/IC therapy included 5 prospective controlled trials (CTs),
the remaining were classified as uncontrolled clinical studies.
The total number of patients included was 801, 228 of whom
had been evaluated in a CT. For CTs, the largest ES for symp-
tom reduction as well as response rate was observed for high
molecular weight hyaluronic acid (HMW-HA), with similar
findings in two uncontrolled studies with HMW-HA. The
number needed to treat to achieve a response to intravesical
therapy was 2.67 for intravesical pentosan polysulphate and
1.31 for HMW-HAwhich were superior to all other instillates.
HMW-HAwas significantly superior in cost effectiveness and
cost efficacy to all other instillation regimes. The present
meta-analysis combined medical and pharmacoeconomic as-
pects and demonstrated an advantage of HMW-HA over other
instillation agents; however, direct comparisons between the
different products have not been performed to date in properly
designed controlled studies.
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Introduction
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a
chronic disease characterised by persistent irritating micturi-
tion symptoms and pain [1]. While there is no general agree-
ment on the precise pathophysiology of this disease, a disorder
at the level of the urine–tissue barrier of the bladder seems to
be the underlying mechanism behind the functional, anatom-
ical and symptomatic manifestations in a considerable number
of cases.
Even if study results are not entirely consistent and, there-
fore, the subject is not closed, a defect in the protective blad-
der’s mucous lining of glycosaminoglycans (GAG) and, thus,
the urine–tissue barrier, has been documented in a subset of
BPS/IC patients [2], mainly demonstrated by a positive potas-
sium sensitivity test (PST) [3–6] and the favourable response
to GAG-restoring agents.
Glycosaminoglycans are classified in four structural
families [7] (heparin and heparan sulphates; chondroitin
and dermatan sulphates; hyaluronan; and keratan sulphate)
and have been used during the last few decades as
intravesical instillations for GAG substitution therapy with
the benefit of delivering high concentrations of the thera-
peutic agent at the target tissue with a low risk of systemic
side effects [8].
The diversity of available therapeutic agents for GAG sub-
stitution may make it difficult for physicians to choose the
optimal treatment for their patients [9, 10]; therefore, the se-
lection of a particular therapeutic regimen should be based on
its capacity for symptom improvement, its impact on the pa-
tient’s quality of life, and its costs [10].
Heparin has commonly been used off-label for BPS/IC
therapy. Pentosan polysulphate (PPS), a semisynthetic
heparin-like GAG of low molecular weight (MW) classically
used for oral therapy of BPS/IC, is also available for
intravesical instillation. Today, hyaluronan, the salt of
hyaluronic acid (HA), and chondroitin sulphate (ChS) are
the two most commonly used GAGs for intravesical treat-
ment, alone or in combination.
Other intravesical instillations containing anaesthetic solu-
tions, such as lidocaine and bupivacaine, are also used in
combination with sodium bicarbonate to control bladder pain
[11], while dimethyl sulfoxide (DMSO), which has a putative
effect on the sensory peripheral nerves of the bladder [12], is
the only intravesical therapy approved by the FDA.
At present, eight agents for intravesical BPS/IC therapy are
commercially available in Europe (Table 1)
Despite the widespread clinical use of each of these sub-
stances, the research-based evidence regarding therapeutic ef-
ficacy is limited and mainly based on uncontrolled trials.
Levels of evidence for the use of these agents have been rated
1b for PPS and heparin, and 2b for HA and ChS in their
different concentrations [13].
The aim of this meta-analytical review is to directly com-
pare the data on the clinical efficacy of products currently
available for intravesical BPS/IC therapy and to assess their




Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) [14] guidelines were used to perform a
comprehensive search for literature on intravesical therapy for
BPS/IC and published in the PubMed/Medline database from
1996 to 2014. The Medical Subject Heading (MESH) search
terms used were: interstitial cystitis, bladder pain syndrome,
intravesical treatment, intravesical chondroitin sulphate,
intravesical hyaluronan, intravesical PPS, intravesical
DMSO, and intravesical lidocaine.
Selection criteria
The PubMed/Medline search allowed us to identify publica-
tions regarding intravesical treatment for BPS/IC. From these,
only studies in English or Spanish reporting clinical results
were reviewed. Further analysis included only studies with a
single compound or a fixed commercially available combina-
tion. Studies were excluded if they:
1. Were performed using intravesical Bcocktails^
2. Did not evaluate intravesical treatment for BPS/IC
Table 1 Intravesical agents for bladder pain syndrome/interstitial







HA Cystistat® 40 mg HMW-HA (0.08 %) in 50 ml
Hyacyst® 40/120 mg HA (0.08/0.24 %) in 50 ml
(MW unknown)
Uromac® 100 mg LMW HA (0.2 %) in 50 ml
CS Gepan instill® 80 mg CS (0.2 %) in 40 ml
Uracyst® 400 mg CS (2 %) in 20 ml
HA/CS Ialuril® 800 mg LMW-HA (1.6 %) / 1 g CS (2 %)
in 50 ml
PPSa Cyst-u-ron® 300 mg PPS (1 %) in 30 ml
DMSO Rimso-50® 27 g DMSO (5.4 %) in 50 ml
HA hyaluronan, CS chondroitin sulphate, PPS pentosan polysulphate
sodium, DMSO dimethyl sulfoxide, HMW high molecular weight, MW
molecular weight, LMW low molecular weight
a Elmiron® is the oral form of pentosan polysulphate sodium (100 mg)
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3. Assessed other related topics, but did not evaluate treat-
ment efficacy (case reports, conference reports etc.)
4. Were defined as review or meta-analysis papers
Data extraction and statistical analysis
Data were extracted from each publication by two indepen-
dent reviewers (CLL and AMG) and included: type of study
according to the presence of a control arm (controlled or un-
controlled clinical trials), randomisation (randomised or non-
randomised controlled trials) and observational studies (pro-
spective or retrospective), type of intravesical solution, total of
patients at baseline (intention-to-treat analysis), total patients
treated (per protocol analysis), number of patients lost to fol-
low-up, therapy regimen (total number of instillations/
frequency of application), instruments/scales used for evalua-
tion of symptoms before and after treatment, and response
rates (RR), considered as the percentage of patients with
symptom reduction after therapy out of the total study sample
[15]. In the absence of an explicitly cited definition for RR,
and according previous publications [16, 17], a reduction of
≥2 on a visual analogue scale (VAS) was considered to be a
response to treatment; the percentage of responders was in-
ferred by calculating the z value, defined as the proportion of
responders within confidence intervals at 95 % (CI 95 %).
The different products were compared with regard to the
average reduction of bladder symptoms on the VAS and the
overall response rates by calculation of BCohen’s d^ [18], a
statistical value for effect size (ES) based on differences be-
tween mean values and the average difference in the propor-
tion of patients with a response to treatment and allows the
difference between the two groups to be quantified using the
standard deviation. While the broadly accepted and cited p
value informs whether an effect from the investigated measure
exists, it does not reveal the size of the effect. For Cohen’s d, a
low value<0.5 shows a small ES, d values>1 are regarded as
large ES.
From the CTs, a post-hoc calculation of a composite VAS/
RR odds ratio (OR) allowed the comparison of results of dif-
ferent intravesical agents with the placebo/control-treated
arms. These values were also used to calculate the number
of patients needed to treat (NNT) to obtain a response.
Finally, the pharmacoeconomic assessment was performed
by multiplying the unit costs by the number of instillations
administered in each CT. Costs per unit and frequency of
instillation (one per week) are very similar for HA and ChS
products; thus, a cost factor of 1 has been assigned for these
two therapies. PPS is less expensive (instillation units cost
40 % of HA/ChS, oral therapy 20 %), but has to be adminis-
tered two or three times per week and may be accompanied by
oral therapy, Thus, a cost factor of 0.4 for intravesical/0.6 for
intravesical and oral therapy has been assumed for PPS trials.
Results
The Medline search led to a total of 345 hits. Initially, all titles
and abstracts were reviewed to identify studies not directly
reporting on BPS/IC or intravesical treatment for BPS/IC,
reviews, and other type of publications not suitable for this
analysis.
From the 33 studies selected according to the outlined
criteria, 11 (33.33 %) assessed intravesical therapy with
HMW-HA 0.08 % (of which one paper also evaluated
intravesical heparin), 7 studies presented the results of ChS
0.2 % therapy (21.21 %), and 3 studies evaluated treatment
with ChS 2.0 % (9.09 %). Results of the combined formula-
tion of LMW-HA + ChS 2.0 % were presented in 4 publica-
tions (12.12 %), 3 papers assessed the results of intravesical
treatment with PPS (9.09 %), 2 with lidocaine (6.06 %), and
another 3 articles reported results with DMSO (9.09 %). No
publications on LMW-HA alone for the treatment of BPS/IC
were retrieved from the search.
The main criteria for the exclusion of studies were reports
on combination therapies with non-GAG substances, duplici-
ty of results (same sample of patients), and results not compa-
rable in a standardised way because of the different instru-
ments used for outcome evaluation. Thus, 2 of the articles
on HMW-HA therapy were excluded from further analysis
because they involved combination with alkalised lidocaine
[19] or oral PPS [20]. Similarly, 2 publications on DMSO
were excluded because of combination therapies (DMSO +
hydrocortisone + heparin sulphate [21] and DMSO + triam-
cinolone [22]). One study with the combination of LMW-HA
1.6 % + ChS 2.0 % [23] was excluded owing to obvious
coincidences with another publication [24].
The majority of the selected publications referred to BPS/
IC therapy, except for 2 papers on ChS 0.2%, which evaluated
the product in patients with overactive bladder [25, 26] and for
the prophylaxis of radiation cystitis [27]; 2 of the excluded
articles reported on the efficacy of a combination of heparin
and lidocaine as an acute analgesic intervention for severe
pain [28, 29].
Two publications on HMW-HA 0.08 % therapy were ex-
cluded because they evaluated symptoms with different non-
standardised scales [30, 31], and in one study in which pa-
tients received intravesical instillations with LMW-HA 1.6 %
+ ChS 2.0 % data on VAS pain scores were missing [32]. The
full text version of one publication for ChS 0.2 % [33] could
not be found after searching several databases. In summary, 14
publications were excluded (Fig. 1).
The final set of 19 articles on intravesical BPS/IC ther-
apy was further qualitatively and quantitatively analysed: 5
studies were prospective controlled trials [34–38], 1 com-
pared different intravesical products [39], 1 paper was de-
signed as a retrospective study [40], and another 1 com-
pared two different regimens of the same product [41]. The
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rest of the trials were classified as uncontrolled clinical
studies (Table 2).
Patients characteristics
The final sample of 19 trials corresponds to a total of 801
patients, with 228 patients evaluated in a CT. Only 4 trials
included male and female patients [15, 35, 44, 45], while the
rest of the studies exclusively included women.
Diagnosis of BPS/IC has been made according to NIDDK/
National Institutes of Health criteria in most studies (one in-
cluding cystoscopic examination [42]), except for three pub-
lications (ESSIC criteria [40], the East Asian guidelines [41]
or clinical perception plus cystoscopy [38]).
Other relevant differences were also detected: six of the
studies included Btreatment-refractory patients^, considered
to be cases with an inadequate response to previous BPS/IC
treatments such as intravesical DMSO [15], heparin and/or
PPS [15, 41] and/or oral drug therapy [24, 43, 47]. One study
only included Bnaïve patients^ (no previous disease-specific
treatment) with a positive PST and a reduction of≥2 points in
symptom score after the first instillation of ChS 0.2 % [44].
Instillation regimen
Initial instillation therapy was performed weekly in 73.7 % of
the studies, but with different follow-up schedules (Table 2).
The instillation procedure was similar inmost studies, with the
exception of one trial, where a solution of lidocaine and sodi-
um bicarbonate was instilled before the PPS to reduce the
procedure-related discomfort and to improve the retention of
the subsequently instilled PPS [38].
Evaluation of efficacy
In most studies a first symptom evaluation was performed at
week 12; however, different scales/scores were used. Among
them, the most commonly used were the O’Leary–Sant
Symptom and Problem Index (ICSI/ICPI), the VAS pain as-
sessment and the Pain, Urgency and Frequency (PUF) score.
According to their design, studies were classified as con-
trolled (Table 3) and uncontrolled (Table 4) trials. All the
studies reviewed reported reductions of VAS pain scores after
treatment, including those controlled using placebo/inactive
controls (Table 3). The ES of VAS reduction was calculated
for each CTand showed significant differences between active
and control groups in all but one study, which compared ChS
2 % with a placebo arm [36]. The largest ES in all CT studies
was observed for HMW-HA in the study by Shao et al. (Fig. 2)
[34], with similar findings in two UCTstudies with HMW-HA
[16, 40] by a superior Bd^ for average VAS difference. Closest
to this VAS reduction were the results obtained using 300 mg
of intravesical PPS [47].
Response rates were compared between intervention arms
by ES assessment only in the trial by Shao et al. [34] with
HMW-HA (d = 2.68 [IC95%:1.82–3.53] vs d = 0.88
[IC95%:0.01–1.76]) for patients without intravesical therapy
(Fig. 3). In CTs, studies with HMW-HA and with ChS 0.2 %
reported superior response rates, with both rates (HMW-HA
vs ChS 0.2 %) not being statistically different.
The post-hoc calculation of composite ES based on VAS
improvement plus RR revealed distinct differences among
studies and products as shown in Fig. 4. OR value was highest
for HMW-HA in the Shao et al. study [34], followed by the
intravesical application of 300 mg of PPS described by Bade
et al. [37].
Pharmacoeconomic evaluation/cost-effectiveness
The NNT for a response to intravesical therapy ranged be-
tween 1.33 (HMW-HA) and 14.81 (ChS 2%), with a negative
value for the PPS combination therapy (Table 5). With this
low NNT, HMW-HAwas also significantly superior with re-
gard to cost-effectiveness and cost efficacy to all other instil-
lation regimes.
Discussion
The present meta-analysis on intravesical BPS/IC therapy
clearly demonstrates the dilemma of the poor scientific evi-
dence currently available for this disease. Owing to the differ-
ent associations regarding the aetiology of the disease and its
Fig. 1 Selection process of the studies included for analysis
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rather low prevalence, most published studies cohorts are het-
erogeneous. The lack of globally accepted instruments for the
evaluation of treatment success resulted in the exclusion of
some trials from this meta-analytical review because the re-
ported outcomes were not comparable.
Even after a careful selection of 19 studies, we still found a
heterogeneous population of 801 patients (mostly women)
who were considered to have BPS/IC according to four dif-
ferent diagnostic criteria and typified as Btreatment-refractory^
(a concept that is not further defined) in 6 studies or as
Btreatment-naïve^ patients in 1 study. Differences in design
are also of particular relevance as only 5 studies (26 %) com-
pared the intravesical formulas against placebo or non-active
controls, while the remainder corresponded to uncontrolled
and observational trials.
Length of treatment and frequency of instillations also dif-
fered: weekly instillations were initially performed in 15 stud-
ies, biweekly or twice weekly instillations were reported for 2
studies each, while the duration of instillation therapy varied
from 6 weeks to 12 months. Similarly, the time period of
follow-up for final evaluation varied from 3 months to 5 years.
All the instruments/scales used for outcome evaluation
(O’Leary–Sant Score, the PUF and VAS for pain) can poten-
tially measure treatment effects, but they are not readily com-
parable with each other. There is also no globally accepted
definition as to the percentage of symptom regression that is
regarded as treatment response. In addition, relatively small
differences in VAS scores before and after treatment may be
statistically but probably not clinically significant. With the
intention to improve the balance between investigational and
Table 2 All studies included for comparison




Instillation protocol Follow-up Evaluation scale
Morales et al. [15] 0.8 % HMW-HA
(Cystistat®)
UCT 25 Weekly for 4 weeks and monthly for
12 months
12 months VAS for pain
Kallestrup et al. [42] UCT 48 Weekly for 4 weeks and monthly for
2 months
3 years VAS for pain
Gupta et al. [43] UCT 38 Weekly for 6 weeks 6 weeks ICSI-ICSP
Riedl et al. [16] UCT 121 Weekly and in response to symptoms 6.5 months VAS for pain
Engelhardt et al. [40] UCT 70 Weekly for 10 weeks 4.9 years VAS for pain
Shao et al. [34] CT 31 After hydrodistention, weekly for
4 weeks and monthly for 2 months
9 months VAS for pain
Lai et al. protocol A a [41] UCT 30 Weekly for 4 weeks and monthly for
5 months
6 months VAS for pain/ICSI-ICPI
Lai et al. protocol B a [41] UCT 30 Every 2 weeks 6 months VAS for pain/ICSI-ICPI
Steinhoff [44] 0.2 % CS (Gepan
instill®)





UCT 165 Weekly for 4 to 6 weeks and one
monthly
3 months VAS for pain
Nickel et al. [46] 2 % CS (Uracyst®/
Uropol S®)
UCT 53 Weekly for 6 weeks and monthly for
4 months
6 months VAS for pain/ICSI-ICPI
Nickel et al. [35] CT 65 Weekly for 6 weeks 3 months VAS for pain/ICSI-ICPI
Nickel et al. [35] CT 98 Weekly for 7 weeks 3 months VAS for pain/ICSI-ICPI
Porru et al. [24] 1.6 % LMW-HA + 2 %
CS (Ialuril®)
UCT Weekly for 12 weeks and biweekly
for 6 months
6 months VAS for pain/ICSI-ICPI
Porru et al. [47] UCT 22 Weekly for 8 weeks and biweekly for
6 months
6 months VAS for pain/ICSI-ICPI
Bade et al. [48] i-PPS 300 mgb
(Elmiron®)
UCT 20 Every 2 weeks for 3 months 3 months Not available
Bade et al. [37] CT 9 Twice weekly for 3 months 3 months ICSI/ICPI
Daha et al.[17] UCT 29 Twice weekly for 10 weeks; monthly
for 6 months
12 months ICSI/ICPI
Davis et al. [38] i-PPS 200 mgc + daily
o-PPS 400 mg
(Elmiron®)
CT 41 Twice a week for 18 weeks 18 weeks VAS for pain/ ICSI-ICPI
Sairanen et al. [39] DMSO UCT 37 Weekly for 6 weeks 3 months VAS for pain
CT controlled trials,UCT uncontrolled trials, VAS visual analogue scale, ICSI/ICPIO’Leary–Sant symptom index and problem index, i-PPS intravesical
PPS, o-PPS oral PPS
a Lai et al. corresponds to two effective protocols with HMW-HA evaluated in the same publication
b Intravesical instillation with 300 mg (three capsules) of Elmiron® + mixed with 50 ml of 0.9 % sodium chloride
c 200 mg or two capsules mixed with 30 ml sterile normal buffered saline
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clinical outcomes, and to extract the maximal information
from the selected set of evaluable studies on intravesical
BPS/IC therapy, refined statistical techniques such as
Cohen’s d along with confidence intervals have been used in
this meta-analytical review to be able to compare the selected
set of evaluable studies.
Interestingly, symptom improvement was observed in all
cases, including those from the placebo/non-active treatment
arms. By far the largest effect sizes (d>2) for symptom reduction
were found in 3 studies performed with HMW-HA [16, 34, 40].
With respect to response rates, effect size measurements
showed similar results for HMW-HA and 0.2 % ChS, and






VAS BT VAS AT VAS ↓ RR (%) VAS effect size RR effect size
Mean SD Mean SD d Min Max d Min Max
Morales et al. [15] 0,8 % HMW-HA
(Cystistat®)
25 6 6.7 2.45 2.7 3.67 4.00 71.0 1.31 0.70 1.92 2.00 1.32 2.68
Kallestrup et al. [42] 20 6 4.7 2.3 3.3 3.0 1.40 65.0 0.53 −0.10 1.16 1.88 1.13 2.62
Gupta et al.a [43] 20 6 – – – – – 55.6 – – – 1.68 0.96 2.40
Riedl et al. [16] 121 12 8.5 1.7 3.5 2.7 5.00 85.0 2.27 1.95 2.60 2.35 2.02 2.67
Engelhardt et al. [40] 48 10 8.15 1.7 2.71 1.96 5.44 85.0 2.97 2.39 3.55 2.35 1.83 2.87
Steinhoffb [44] 0.2 % CS
(Gepan instill®)
13 – – – – – – 92.3 – – – 2.58 1.83 3.33
Nordling and van
Ophoven [45]
165 8 5.2 2.57 3.3 2.57 1.90 76.7 0.74 0.52 0.96 2.13 1.86 2.4
Nickel et al. [46] 2 % CS
(Uracyst®/
Uropol S®)
53 10 6.9 1.8 4.3 2.3 2.60 60.0 1.27 0.85 1.69 1.77 1.32 2.22
Porru et al. [24] 1,6 % HA+ 2 %
CS (Ialuril®)
23 12 5.4 2.8 3.6 2.5 1.80 46.0 0.68 0.08 1.27 1.49 0.84 2.14
Porru et al. [47] 20 10 5.6 2.3 3.2 3.1 2.40 53.48 0.89 0.24 1.54 1.64 0.92 2.36
Bade et al. [48] i-PPS 300 mg 6 24 7.5 1.38 4.17 2.3 3.33 66.7 1.81 0.47 3.15 1.91 0.55 3.28
Daha et al. [17] 25 22 – – – – – 16.0 – – – 0.82 0.25 1.4
VAS visual analogue pain score, BT before treatment, AT after treatment, RR response rate, d=Cohen’s d, i-PPS intravesical instillation with 300 mg
(three capsules) of Elmiron® + mixed with 50 ml of 0.9 % sodium chloride
a 6 weeks
b 24 weeks
Fig. 2 Randomised controlled
trials: effect size of average VAS
reduction. 95%CI 95 %
confidence intervals, HMW-HA
high molecular weight hyaluronic
acid 0.08 %, ChS 2% chondroitin
sulphate 2 %, o-PPS oral dose of
pentosan polysulphate, i- PPS
intravesical instillation with
pentosan polysulphate
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for PPS. If only CTs were included in the analysis, HMW-HA
was significantly superior to all other instillates (Table 3). The
closest results on efficacywere observedwith intravesical PPS
[37] and a combination of intravesical plus oral PPS [38]; this
last combined strategy reported by Davis et al. [38], however,
showed a higher RR in patients who received oral PPS alone
(90 vs 85.7 %).
In the pharmacoeconomic approach of CTs, a clear ad-
vantage for HMW-HA was observed: the NNT for a
treatment response was 1.31 for HMW-HA vs 2.74 for
intravesical PPS and 5.51 for ChS 2 %. Cost efficacy
(treatment costs * NNT) and cost effectiveness (treatment
costs/responders) were higher for HMW-HA. Cost effec-
tiveness was less than half for ChS and only about a third
for PPS compared with HMW-HA, and cost efficacy was
less than 25 % for ChS compared with HMW-HA.
However, these results are based on a small number of
studies with final analysis.
Fig. 3 Randomised controlled
trials: effect size of the response
rates. 95%CI 95 % confidence
intervals, HMW-HA high
molecular weight hyaluronic acid
0.08 %, ChS 2% chondroitin
sulphate 2 %, o-PPS oral dose of
pentosan polysulphate, i- PPS
intravesical instillation with
pentosan polysulphate
Fig. 4 Composite effect size of
response rates and VAS
reduction: active treatments
versus placebo (OR 95%CI).
95%CI 95 % confidence
intervals, VAS visual analogue
scale of pain, OR odds ratio
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The present meta-analytical analysis adds important infor-
mation to the body of published evidence and is partly con-
tradictory to systematic reviews that have been published in
the past. In particular, ES assessment of outcome parameters
facilitates the comparison of results with different GAG prod-
ucts for BPS/IC.
Madersbacher et al. [7] searched the literature for all
forms of chronic cystitis, including radiation cystitis and
also OAB (which is not considered a form of chronic cys-
titis) and excluded all but 27 publications for further anal-
ysis. They concluded that ChS is superior to other
intravesical GAG substitutes. However, in their review,
368 patients who were treated with ChS had a diagnosis
of OAB, 20 patients a diagnosis of radiation cystitis [27],
and only 118 patients were Bexclusively^ diagnosed with
BPS/IC. The authors also state that no significant superi-
ority versus controls was observed in the single controlled
study on ChS 2 % that was reviewed [35].
Giannantoni et al. [49] evaluated CTs and UCTs on a mul-
titude of therapies for BPS/IC, including behavioural, dietary,
interventional, pharmacological and surgical therapies. In
their systematic review not a single study on HA therapy
was included. Given the high number of publications on HA
in BPS/IC reporting superiority to other intravesical agents,
this review is presumably incomplete. The authors conclude
that evidence of BPS/IC therapy is limited, and that only the
oral drugs cyclosporine A and amitriptyline showed signifi-
cant ES on the classical BPS/IC symptoms of pain and fre-
quency/urgency.
Fall et al. [13] reviewed the literature to find an evidence
base for treatment decisions in BPS/IC. Their conclusions
were: level of evidence (LE) 1b/grade of recommendation
(GR) A for intravesical PPS, LE 2b/GR B for HA and for
ChS, and LE 3/GR C for intravesical heparin.
The review performed by Matsuoka et al. [50] included
four treatment modalities for BPS/IC: resiniferatoxin,
Bacillus Calmette–Guerin (BCG), oxybutynin and alkalinised
lidocaine; as no GAG substitutes were evaluated, their results
are not comparable with our analysis.
In conclusion, this meta-analytical review provides evi-
dence of the positive effects of intravesical GAG therapy for
BPS/IC and that this treatment may significantly improve pa-
tients’ symptoms. Single reports even suggest that complete
and permanent remission is possible in a subgroup of patients
that has not yet been well defined [40, 42].
If medical and pharmacoeconomic aspects are com-
bined, HMW-HA seems to have some advantage over
other instillation agents. Despite these findings, direct
comparisons between the different products have not
been performed to date in properly designed controlled
studies.
The present meta-analysis suffers from the limited num-
ber of controlled accessible studies on intravesical thera-
pies for BPS/IC and non-standardised response criteria.
Many studies had to be excluded because of non-
comparable inclusion criteria, treatment combinations and
evaluation instruments. However, it gives a complete sum-
mary of all the data currently available and, by assessing
the effect size, makes it possible to compare the relevance
of the individual studies.
Acknowledgements Dr Agustí Martí Gil and Dr Cindy L. Larios from
the Medical Department of Clever Instruments S.L. (Barcelona, Spain)
collaborated as independent reviewers.
Table 5 Pharmacoeconomic evaluation
Product HMW-HA 0.08 %
(Cystistat®)
2 % CS (Uracyst®-Uropol S®) i-PPS 300 mg
(Elmiron®)
i-PPS 200 mg + o-PPS
400 mg (Elmiron®)
Study Shao et al. [34] Nickel et al. [35] Nickel et al. [36] Bade et al. [37] Davis et al. [38]
Cost per instillation 1 1 1 0.4 0.6
Number of instillations 6 6 8 24 36
Cost of treatment (CT) 6 6 8 9.6 21.6
%Responders placebo/control 0.182 0.233 0.313 0.200 0.90
%Responders active treatment 0.933 0.4145 0.38 0.40 0.857
Odds ratio (95%IC) 76.5 (6.08; 963.06) 2.33 (0.76; 7.17) 1.35 (0.58; 3.11) 3.19 (0.42; 24.38) 0.67 (0.10; 4.48)
Absolute risk reduction (95%CI) − 0.75 (−1–0; −0.50) −0.18 (−2.88; 0.18) −0.07 (−0.26; 0.12) −0.20 (−0.59; 0.19) 0.04 (−0.16; 0.24)
NNT (95%CI) 1.33 (1.0; 2.0) 5.51 (2.4; 18.84) 14.81 (3.92; 8.31) 2.67 (0.36; 19.71) −23.33 (−4.13; 6.40)
Cost-effectiveness (CT/%responders) 6.43 14.49 21.05 21.62 25.20
Cost efficacy (CT aNNTs) 7.98 33.06 118.48 25.63 503.93
HMW-HA high molecular weight hyaluronic acid,CS chondroitin sulphate, i-PPS intravesical pentosan polysulphate, o-PPS oral pentosan polysulphate,
NNT number needed to treat to obtain a response
a Response rates correspond to those presented in the articles [29, 30, 31, 33] and/or calculated by total of responders/total patients with per protocol
results [32]
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